CTMX Key Statistics, Chart & Performance
The current stock price of CTMX is 5.54 USD. In the past month the price increased by 31.9%. In the past year, price increased by 521.7%.
CTMX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTMX. When comparing the yearly performance of all stocks, CTMX is one of the better performing stocks in the market, outperforming 99.41% of all stocks.
CTMX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CTMX. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability.
CTMX Financial Highlights
Over the last trailing twelve months CTMX reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 140.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.66% | ||
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| Debt/Equity | 0 |
CTMX Forecast & Estimates
14 analysts have analysed CTMX and the average price target is 7.21 USD. This implies a price increase of 30.2% is expected in the next year compared to the current price of 5.54.
For the next year, analysts expect an EPS growth of -105.14% and a revenue growth -31.15% for CTMX
CTMX Ownership
CTMX Latest News, Press Relases and Analysis
About CTMX
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Company Info
CYTOMX THERAPEUTICS INC
151 Oyster Point Blvd., Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Sean A. McCarthy
Employees: 119
Phone: 16505153185
CYTOMX THERAPEUTICS INC / CTMX FAQ
What does CTMX do?
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
What is the current price of CTMX stock?
The current stock price of CTMX is 5.54 USD. The price decreased by -3.15% in the last trading session.
Does CTMX stock pay dividends?
CTMX does not pay a dividend.
What is the ChartMill rating of CYTOMX THERAPEUTICS INC stock?
CTMX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is CYTOMX THERAPEUTICS INC (CTMX) stock traded?
CTMX stock is listed on the Nasdaq exchange.
Should I buy CTMX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTMX.